Related Experiment Videos
U.S. experience with valproate in manic depressive illness: a multicenter trial
1Department of Psychiatry, Columbia University, New York, NY.
The Journal of Clinical Psychiatry
|March 1, 1989
Summary
Valproate, a medication for seizures, shows promise in treating bipolar disorder and schizoaffective disorder, with about two-thirds of patients with refractory bipolar disorder responding well. Monitoring drug levels is crucial for effectiveness and safety.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Valproic acid and divalproex sodium are established treatments for seizure disorders.
- Preliminary research suggests valproate's efficacy in treating mood disorders.
Purpose of the Study:
- To evaluate the effectiveness of valproate in treating manic-depressive illness, including acute mania, bipolar episode prevention, and schizoaffective disorder.
- To assess valproate's efficacy and side effect profile in treatment-resistant patients with affective disorders.
Main Methods:
- Review of uncontrolled and controlled studies on valproate treatment for affective disorders.
- Analysis of preliminary results from an ongoing community-based open trial of valproate.
Main Results:
- Approximately two-thirds of patients with refractory bipolar disorder responded to acute valproate therapy.
- Moderate response observed in schizoaffective patients; valproate appeared less effective for depression.
- Valproate demonstrated a favorable side effect profile in preliminary trials.
Conclusions:
- Valproate is a frequently effective treatment option for refractory bipolar disorder and schizoaffective disorder.
- Monitoring plasma drug levels is recommended to optimize efficacy and minimize toxicity.
- Further research is warranted to fully elucidate valproate's role in affective disorder treatment.